Neuberger Berman Group LLC Erasca, Inc. Call Options Transaction History
Neuberger Berman Group LLC
- $124 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ERAS
# of Institutions
153Shares Held
217MCall Options Held
258KPut Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$54.1 Million1.52% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.3MShares$48.4 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$42.5 Million4.49% of portfolio
-
Logos Global Management LP San Francisco, CA15MShares$35.7 Million2.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$34.5 Million0.63% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $291M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...